Research ArticleAccepted Article
Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Grad Dip, Hedley Griffiths, Lynden Roberts, Kathleen Tymms and Geoff Littlejohn
The Journal of Rheumatology December 2019, jrheum.190535; DOI: https://doi.org/10.3899/jrheum.190535
Peter Youssef
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Bruno Marcal
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Peter Button
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Matt Truman
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Paul Bird
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Grad Dip
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Hedley Griffiths
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Lynden Roberts
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Kathleen Tymms
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Geoff Littlejohn
From Royal Prince Alfred Hospital, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia Roche Products Pty Limited, Sydney, NSW, Australia; OzBiostat Pty. Ltd., Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Barwon Rheumatology Service, Geelong, VIC, Australia; Monash Rheumatology, Clayton, VIC, Australia; Canberra Rheumatology, Canberra, ACT, Australia; Monash University, Clayton, VIC, Australia. Funding: The study was supported by Roche Products Pty Limited (Australia). Author Conflict of Interest: PY reports honoraria and consultancy fees from Roche Products, Pty. Limited, AbbVie, Novartis and Eli Lilly, all outside the submitted work. BM is an employee of Roche Products Pty. Limited and reports stock ownership at Roche. PButton was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study. MT was an employee of Roche Products Pty. Limited until December 2017 and then worked as a consultant statistician during the conduct of the study; and he reports stock ownership at Roche. PBird does not have anything to declare. HG reports consultancy fees from Roche Products, Pty. Limited, outside the submitted work. LR does not have anything to declare. KT reports personal fees and non-financial support from Roche Products, Pty. Limited, non-financial support from Bristol-Myers Squibb, non-financial support from UCB, outside the submitted work. GL reports consultancy fees from Roche Products, Pty. Limited, Janssen, and AbbVie; and honoraria fees from Sanofi, all outside the submitted work. Address correspondence to Professor Peter Youssef, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 2050, University of Sydney. Email: pyoussef@med.usyd.edu.au
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Grad Dip, Hedley Griffiths, Lynden Roberts, Kathleen Tymms, Geoff Littlejohn
The Journal of Rheumatology Dec 2019, jrheum.190535; DOI: 10.3899/jrheum.190535
Accepted manuscript
Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Grad Dip, Hedley Griffiths, Lynden Roberts, Kathleen Tymms, Geoff Littlejohn
The Journal of Rheumatology Dec 2019, jrheum.190535; DOI: 10.3899/jrheum.190535